CA
PHAS

CHI Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

CHI Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-750,000
Closed -$450K – 30
2022
Q2 		$450K Buy
+750,000
New +$718K 0.17% 25

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PTP
Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return

CHI Advisors's PHAS Position: Q3 2022 in Review

CHI Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2022, closing a stake of 750,000 shares — an estimated $450K sold.

CHI Advisors first reported a position in PHAS in Q2 2022 and held it in 1 quarter. The position peaked at $450K in Q2 2022. 38 funds tracked by Wall St. Rank hold PHAS as of Q3 2022.

  • CHI Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • CHI Advisors sold 750,000 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $450K.
  • CHI Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • CHI Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $450K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on CHI Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.